Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

4D Molecular Therapeutics (FDMT) Gross Margin: 2020-2025

Historic Gross Margin for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to 100.00%.

  • 4D Molecular Therapeutics' Gross Margin changed negligibly% to 100.00% in Q3 2025 from the same period last year, while for Sep 2025 it was 100.00%, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of 100.00% for FY2024, which is negligibly% changed negligibly from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Gross Margin of 100.00% as of Q3 2025, which was down 0.00% from 100.00% recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' Gross Margin ranged from a high of 100.00% in Q1 2021 and a low of 100.00% during Q1 2021.
  • For the 3-year period, 4D Molecular Therapeutics' Gross Margin averaged around 100.00%, with its median value being 100.00% (2025).